![]() If the Supreme Court is asked to weigh in this week, the cases will serve as a major test of the Supreme Court following last year’s decision in Dobbs v. ![]() The DOJ acknowledged the “significant tension” between the two rulings in a filing in the Washington case Monday, where it asked the judge to “clarify” the government’s obligations under the two court rulings. Mary Ziegler, a law professor at the University of California Davis School of Law who specializes in reproductive law, said the “dueling” nature of the rulings from Texas and Washington will likely accelerate the appellate process “just because it is fairly untenable to tell the FDA to do two contradictory things.” The challenge to mifepristone approval, and through that medication abortion availability, could change quickly over the course of the next few days, experts said. ![]() “If we get to a situation where everyone has denied stays and Judge Kacsmaryk’s injunction has taken effect, I think there will be some difficult questions I think need to be addressed and some conversations that will need to have with FDA around what happens next, ” Ellsworth said during a press call Monday. Court of Appeals for the 5th Circuit to keep the current approval on mifepristone while the case goes through the courts. The FDA and Danco Laboratories, which is one of two companies that produce mifepristone for abortions domestically, on Monday appealed Kacsmaryk’s ruling and asked the U.S. District Court for the Eastern District of Washington ruled that the agency should not alter the status quo related to the drug-but that ruling would only apply to the 17 states and Washington, D.C., involved in that lawsuit. District Court for the Northern District of Texas suspended the FDA approval of mifepristone in an order that would stop the manufacture and distribution of the drug this Saturday. On Friday, Judge Matthew Kacsmaryk of the U.S. The moves come as experts expect fast-paced court action that could easily head to the Supreme Court as soon as this week on the Food and Drug Administration’s approval and regulations of mifepristone, which was first approved in 2000 to end pregnancies. The Justice Department and several Democrat-led states took steps Monday to preserve access to a commonly used medication abortion drug after dueling federal court rulings about its availability.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |